Trial Profile
Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor (Ketoconazole study)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Dec 2015
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Ketoconazole (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism
- Focus Pharmacokinetics; Therapeutic Use
- 28 Dec 2015 New trial record